SRTD Biotech Seed: €31.5M

Nov 10, 2026Verified by OSH — Confirmed by at least two independent sources or a primary document (filing, official announcement).

SRTD Biotech raised €31.5 million (about $35.26 million) in a seed round led by Mérieux Equity Partners and NRW.BANK and Boehringer Ingelheim Venture Fund, announced Nov. 10.

Facts

Company: SRTD Biotech
Amount: €31.5 million (about $35.26 million)
Currency: EUR
Stage: Seed
Announced: Nov 10, 2026
Instrument: Equity
FX rate: 1 EUR = 1.1193 USD on Nov 9, 2026

Investors

Led by: Mérieux Equity Partners NRW.BANK Boehringer Ingelheim Venture Fund
Participants: Lilly Ventures HTGF Anobis Asset

Use of funds

Advance the seRNA platform that expresses only in diseased cells and LNP delivery, and support preclinical work in preparation for an IND application.

As stated by the company.

Sources

1.Why Lilly and Boehringer backed a German startup’s mRNA ‘on-off switch’ in a €31.5M seed — TFN — techfundingnews.com
2.mRNA therapy company SRTD Biotech has complet... — chaincatcher.com
3.SRTD Biotech Raises €31.5M in Seed Funding — finsmes.com

Verified by OSH — Confirmed by at least two independent sources or a primary document (filing, official announcement).Last verified Nov 10, 2026